Abstract
Recent advances in management of anti-coagulation in atrial fibrillation
Highlights
Atrial fibrillation is an arrhythmia characterized by chaotic electrical activity in the atrium arising as a spontaneous ectopy mainly from the pulmonary veins
Pooled analysis of non-vitamin K oral anti-coagulants (NOACs) trials in the prevention of stroke in patients with Atrial Fibrillation (AF) demonstrated that in comparison to warfarin these agents resulted in significant reductions in stroke or systemic embolic events, reduced intracranial hemorrhage and all-cause mortality (NAOCs and warfarin exhibited similar extent of major bleeding)[20]
Studies in patients with AF undergoing ablation have shown that major bleeding and stroke/thromboembolic rates were similar with apixaban, rivaroxaban, and warfarin[29,30]
Summary
Atrial fibrillation is an arrhythmia characterized by chaotic electrical activity in the atrium arising as a spontaneous ectopy mainly from the pulmonary veins. There is a significant risk of stroke in patients with AF due to formation of clot in left atrial appendage. Management of Anti-Coagulation in Atrial Fibrillation to prevent cardioembolic stroke in patients with AF.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
